Investor Strategy Panel: From Specialist Therapy to Standard of Care: What Must Happen for RLTs to Become a Commercially Scalable Oncology Modality?

Name: Investor Strategy Panel: From Specialist Therapy to Standard of Care: What Must Happen for RLTs to Become a Commercially Scalable Oncology Modality?
Start: 2026-12-02T18:00
Location: Renaissance London Heathrow Hotel

Targeted Radiopharmaceuticals Summit EU 2026 · 2 December 2026 · 18:00

Investor Strategy Panel: From Specialist Therapy to Standard of Care: What Must Happen for RLTs to Become a Commercially Scalable Oncology Modality? was a session at Targeted Radiopharmaceuticals Summit EU 2026 on 2 December 2026 in London, with 4 speakers on record.

Speakers

Kemp Dolliver — Panelist Director of Research, Brookline Capital Markets
Kevin Madagan — Panelist Partner, McGuireWoods
Daniel Squair — Panelist S&E Manager, Jarlen Capital
Ian Poburenny — Panelist Director, Rothschild & Co.